EUVIMEDEUVIMED entdecken
Multizentrische StudieÄquivalenzstudieRandomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms

Manuel Ritter, Johannes Stein, Neil Barber, Jas Kalsi, Rick Popert, Edward Bass, Robert Németh, Matthias Schmid, Simon Gloger, Burkhard Ubrig, Arkadiusz Miernik, Christian Gratzke

European Urology Focus · 2026

DOI: 10.1016/j.euf.2026.01.006 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Urology Focus, 2026. Verfasst von Manuel Ritter und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. Electronic address: mritter@ukbonn.de. Hauptthemen laut MEDLINE: Lower Urinary Tract Symptoms, Aquablation, Prostatic Hyperplasia, Transurethral Resection of Prostate. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Aquablation and laser enucleation of the prostate (LEP) are treatments for alleviation of lower urinary tract symptoms (LUTS) that have not yet been directly compared in a prospective randomized trial. This study was designed to evaluate these treatments in terms of LUTS improvement and safety in men with large prostates. METHODS: WATER III is an investigator-initiated, international, multicenter, nonblinded, prospective noninferiority trial that includes randomized and nonrandomized participants. Eligible patients had moderate to severe LUTS and a large prostate volume (80-180 ml). The primary efficacy endpoint was the change in International Prostate Symptom Score (IPSS) from baseline to 3 mo. The primary safety endpoint was the incidence of Clavien-Dindo (CD) grade ≥2 or persistent CD grade 1 complications that had not resolved by 3 mo. Bayesian analyses were used to assess noninferiority. KEY FINDINGS AND LIMITATIONS: A total of 202 men were enrolled in the study, of whom 186 underwent surgery (98 Aquablation, 88 LEP). At 3 mo, data were available for 170 patients, including 66 randomized and 104 nonrandomized men. Both treatments showed similar mean IPSS improvement at 3 mo: -12.9 ± 6.9 with Aquablation versus -13.1 ± 7.5 with LEP, with an estimated difference of 0.93 (95% credible interval [CrI] -1.48 to 3.53) and noninferiority probability of >0.999. The incidence of CD grade ≥2/persistent grade 1 complications was 40.8% in the Aquablation group versus 56.8% in the LEP, with an estimated difference of -9.4% (95%CrI -31.8% to 12.9%; noninferiority probability 0.952). Retrograde ejaculation was less frequent after Aquablation (14.8% vs 77.1%; p < 0.001). Persistent stress urinary incontinence (SUI) was absent following Aquablation versus 9.3% after LEP (p < 0.05). CONCLUSIONS AND CLINICAL IMPLICATIONS: Aquablation demonstrated noninferior short-term LUTS relief and similar safety compared to LEP, with superior ejaculation preservation and avoidance of SUI in short-term follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lower Urinary Tract SymptomsAquablationProstatic HyperplasiaTransurethral Resection of ProstateLaser TherapyHumansMaleProspective StudiesAgedMiddle AgedTreatment OutcomePostoperative Complications

Stichwörter der Autor:innen

Aquablation therapyBenign prostatic hyperplasiaHolmium laser enucleation of the prostateLower urinary tract symptomsThulium laser enucleation of the prostate

Autor:innen und Institutionen

  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany. Electronic address: mritter@ukbonn.de.
  • Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany.
  • Frimley Health NHS Foundation Trust, Camberley, UK.
  • Guy's and St. Thomas' NHS Foundation Trust, London, UK.
  • Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany.
  • Center for Minimally Invasive and Robotic Urology, Augusta Hospital Bochum, Witten/Herdecke University, Bochum, Germany.

Zitieren

APA

Ritter, M., Stein, J., Barber, N., Kalsi, J., Popert, R., Bass, E., Németh, R., Schmid, M., Gloger, S., Ubrig, B., Miernik, A., & Gratzke, C. (2026). WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. European Urology Focus. https://doi.org/10.1016/j.euf.2026.01.006

Vancouver

Ritter M, Stein J, Barber N, Kalsi J, Popert R, Bass E, et al. WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms. European Urology Focus. 2026. doi:10.1016/j.euf.2026.01.006

BibTeX
@article{Ritter2026,
  author = {Ritter, Manuel and Stein, Johannes and Barber, Neil and Kalsi, Jas and Popert, Rick and Bass, Edward and Németh, Robert and Schmid, Matthias and Gloger, Simon and Ubrig, Burkhard and Miernik, Arkadiusz and Gratzke, Christian},
  title = {WATER III: A Prospective, Partially Randomized Trial of Aquablation Therapy Versus Transurethral Laser Enucleation of the Prostate for Treatment of Lower Urinary Tract Symptoms},
  journal = {European Urology Focus},
  year = {2026},
  doi = {10.1016/j.euf.2026.01.006}
}
Kostenlos starten →